Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communications Arising
  • Published:

MAGI3–AKT3 fusion in breast cancer amended

Nature volume 520, pages E11–E12 (2015)Cite this article

Subjects

arising from S. Banerji et al. Nature 486, 405–409 (2012); doi:10.1038/nature11154

Banerji et al.1 described a novel MAGI3–AKT3 rearrangement in breast cancer, enriched in triple-negative tumours; the report was highly encouraging as targeted therapies could potentially serve as a new and much needed option to treat this highly aggressive breast cancer subtype. We sought to confirm the presence of this rearrangement in 236 samples of triple-negative breast cancer (TNBC) by using fluorescent in situ hybridization (FISH) and reverse transcription–polymerase chain reaction (RT–PCR), and in 84 additional cases from The Cancer Genome Atlas by using FusionSeq. No evidence of the fusion was found in any of the tumours studied. Our study confirms that MAGI3–AKT3 fusion is not a recurrent event in triple-negative breast cancer, which should be acknowledged before considering the evaluation of targeted therapies in clinical trials. There is a Reply to this Brief Communication Arising by Pugh, T. et al. Nature 520, http://dx.doi.org/10.1038/nature14266 (2015).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Absence of MAGI3–AKT3 fusion in triple-negative breast cancer.

References

  1. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–409 (2012).

    Article  ADS  CAS  Google Scholar 

  2. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109, 1721–1728 (2007).

    Article  Google Scholar 

  3. Pal, S. K., Childs, B. H. & Pegram, M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res. Treat. 125, 627–636 (2011).

    Article  CAS  Google Scholar 

  4. Craig, D. W. et al. Genome and transcriptome sequencing in prospective refractory metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol. Cancer Ther. 12, 104–116 (2013).

    Article  CAS  Google Scholar 

  5. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med. 17, 1646–1651 (2011).

    Article  CAS  Google Scholar 

  6. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011).

    Article  ADS  CAS  Google Scholar 

  7. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006).

    Article  CAS  Google Scholar 

  8. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).

    Article  ADS  CAS  Google Scholar 

  9. Sboner, A. et al. FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol. 11, R104 (2010).

    Article  CAS  Google Scholar 

  10. Pflueger, D. et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 21, 56–67 (2011).

    Article  CAS  Google Scholar 

  11. Mosquera, J. M. et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom. Cancer 52, 538–550 (2013).

    Article  CAS  Google Scholar 

  12. Mosquera, J. M. et al. Novel miR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosom. Cancer 52, 1075–1087 (2013).

    Article  CAS  Google Scholar 

  13. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Juan-Miguel Mosquera and Sonal Varma: These authors contributed equally to this work.

  2. Mark A. Rubin and Sandra J. Shin: These authors jointly supervised this work.

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, 10065, New York, USA

    Juan-Miguel Mosquera, Sonal Varma, Chantal Pauli, Theresa Y. MacDonald, Jossie J. Yashinskie, Andrea Sboner, Mark A. Rubin & Sandra J. Shin

  2. Institute for Precision Medicine of Weill Cornell Medical College and New York-Presbyterian Hospital, New York, 10021, New York, USA

    Juan-Miguel Mosquera, Chantal Pauli, Andrea Sboner & Mark A. Rubin

  3. Institute for Surgical Pathology, University Hospital, Zürich, Switzerland, 8091

    Chantal Pauli, Zsuzsanna Varga & Holger Moch

  4. Institute for Computational Biomedicine, Weill Cornell Medical College, New York, 10021, New York, USA

    Andrea Sboner

Authors
  1. Juan-Miguel Mosquera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonal Varma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chantal Pauli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theresa Y. MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jossie J. Yashinskie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zsuzsanna Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Sboner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Holger Moch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mark A. Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sandra J. Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.M.M. performed experimental work and wrote the paper; S.V. performed experimental work and wrote the paper; C.P., T.Y.M., J.J.Y., Z.V. and H.M. performed experimental work; A.S. performed data analysis; S.J.S. performed project planning and revised the paper; M.A.R. designed research, performed project planning and revised the paper.

Corresponding authors

Correspondence to Mark A. Rubin or Sandra J. Shin.

Ethics declarations

Competing interests

Declared none.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mosquera, JM., Varma, S., Pauli, C. et al. MAGI3–AKT3 fusion in breast cancer amended. Nature 520, E11–E12 (2015). https://doi.org/10.1038/nature14265

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature14265

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research